{"url_path":"/sec/cik-0001012477/8-k/2026-01-12/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-01-12","source_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-002870-index.html","accession_number":"0001104659-26-002870","cik":"0001012477","ticker":null,"issuer_name":"AVADEL PHARMACEUTICALS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-002870-index.html","primary_entity_key":"0001012477","primary_entity_name":"AVADEL PHARMACEUTICALS PLC"},"word_count":315,"has_tables":true,"body_markdown":"false\n0001012477\n\n0001012477\n\n2026-01-12\n2026-01-12\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant\nto Section 13 or Section 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report\n(Date of earliest event reported)**: January 12, 2026\n\n \n\n \n\n \n\n**AVADEL PHARMACEUTICALS PLC**\n\n**(Exact name of registrant as specified\nin its charter)**\n\n \n\n \n\n \n\n**Ireland**\n**001-37977**\n**98-1341933**\n\n(State or other jurisdiction\n(Commission\n(IRS Employer\n\nof incorporation)\nFile Number)\nIdentification No.)\n\n \n\n**10\nEarlsfort Terrace**\n\n**Dublin 2**, **Ireland,****D02\nT380**\n\n** **\n\n**Not Applicable**\n\n(Address of principal executive offices)\n(Zip Code)\n\n \n\n**Registrant’s telephone number, including\narea code**: **+353****1 901 5201**\n\n \n\n**Not Applicable**\n\n(Former name or former address,\nif changed since last report)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation to the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section\n12(b) of the Act:\n\n \n\n \n\nTitle of each class\nTrading Symbol(s)\nName\nof each exchange on which registered\n\nOrdinary\nShares, nominal value $0.01 per share\n\nAVDL\n\nThe Nasdaq Global Market\n\n \n\nIndicate by check mark whether the registrant is an emerging\ngrowth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the\nregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ¨"}